Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Venture Partner operating in the Medical space. If you think a Venture Partner is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Jim Faulkner
Venture Partner of Apple Tree Partners
Jim Faulkner is a venture partner at ATP. A highly experienced biopharmaceutical development leader with specialist skills in gene and cell therapy, he has been significantly involved in taking more than 25 different medicines into the clinic, including multiple CAR-T assets. Most recently, Jim headed Product Delivery for Autolus Ltd, a clinical-stage CAR-T company spun out of University College London. During his tenure, he set up and led a team of over 75 scientists and engineers in the US and UK responsible for process development, technical operations, engineering and supply chain, and he served on the leadership team that took Autolus from start-up to successful IPO in three years. Prior to that, Jim held various leadership roles at GlaxoSmithKline, including overseeing the chemistry, manufacturing and controls (CMC) development and supply of a portfolio of pioneering product types that included gene and cell therapies, oligonucleotides, therapeutic enzymes, and molecular chaperones, and playing a significant role in the successful filing of the first-ever autologous ex vivo gene/cell therapy product license (for Strimvelis™). He started his career at British Biotech, the first biotechnology company to be publicly listed in the UK. Jim earned a BSc in biotechnology from the University of Leeds and completed his PhD in molecular biology at the Centre for Applied Microbiology and Research.
Follow Jim Faulkner:
About Apple Tree Partners: Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Rajesh Chopra
Venture Partner of Apple Tree Partners
Raj Chopra is a venture partner at ATP. At The Institute of Cancer Research in London, as director of the Cancer Research UK Cancer Therapeutics Unit, he led one of the largest academic drug discovery groups in the world and focused on targeted protein degradation and complex 3D cell culture models. Raj also worked at Celgene from 2009 to 2016 as corporate vice president of Translational and Early Drug Development, leading an international team of more than 100 scientists. Before joining Celgene, he held leadership positions in AstraZeneca’s Oncology Therapeutics group in the UK and US. Raj started his academic career as the director of Hematological Oncology at Christie Hospital and was group leader at the Paterson Institute of Cancer Research, both located in Manchester, UK. He is a non-executive director of Artios Pharma, established to develop a next-generation DNA damage response target pipeline of cancer therapeutics, and co-founder of Monté Rosa Therapeutics, a biotech focused on targeted protein degradation. Raj trained in medicine at University College London, where he earned his PhD in medicine, cell and molecular biology. He is a fellow of the Royal College of Physicians of London, the Royal College of Pathologists, and the Royal Society of Biology.
Follow Rajesh Chopra:
About Apple Tree Partners: Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Andrew Bayliffe
Venture Partner of Apple Tree Partners
Andrew Bayliffe is a venture partner at ATP. With more than 20 years of leadership experience in the biopharmaceutical industry, he possesses expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas. Most recently, at GlaxoSmithKline (GSK), he served as head of the Fibrosis and Lung Injury Discovery unit at GSK’s R&D headquarters in Stevenage, UK, and held senior roles in antibody discovery and development in the US and UK. Andrew is an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast. He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.
Follow Andrew Bayliffe:
About Apple Tree Partners: Apple Tree Partners is a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Andrew Witty
Venture Partner of Hatteras Venture Partners
Andrew became Chief Executive Officer of GlaxoSmithKline plc on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined Glaxo in 1985 and has held a variety of Sales and Marketing roles in the UK and abroad including working in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields. Outside of the UK Andrew has worked in South Africa, the USA and Singapore where he led the Group’s operations as Senior Vice President, Asia Pacific. While in Singapore Andrew was a Board Member of the Singapore Economic Development Board and the Singapore Land Authority. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In 2003 Andrew was appointed President of GSK Europe and joined GSK’s Corporate Executive Team. Andrew has served in numerous advisory roles to Governments around the world including South Africa, Singapore, Guangzhou China and the UK, where he was a member of the Prime Minister’s Business Advisory Group from 2010 – 2015. He was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry in the 2012 New Year Honours List. In 2014, Andrew was appointed to be a Business Ambassador for the UK Government and in 2015, Andrew became a member of the China-Britain Business Council Advisory Council. Andrew is Chancellor of the University of Nottingham, a position he took up on 1 January 2013. Andrew has a Joint Honours BA in Economics from the University of Nottingham.
Follow Andrew Witty:
About Hatteras Venture Partners, University of Nottingham: Hatteras Venture Partners is a North Carolina-based venture capital firm that finances biomedical companies.
Michael Carter
Venture Partner of SV Health Investors
Dr. Michael Carter joined SVLS in 1998 as a Venture Partner. From 1986 to 1998 Michael was on the board of ICI/Zeneca Pharmaceuticals and from 1995 – 1998 was also a board member of Salick Healthcare – a US subsidiary of Zeneca. He was International Marketing Director at ICI/Zeneca Pharmaceuticals; in addition as International Medical Director he was involved in the clinical and commercial development of over 20 new medicines. For 10 years (1986 – 1996) he was a member of the UK Government’s Medicines Commission. He has also worked at Roche Products as Director of the Pharmaceutical Division. Before entering the pharmaceutical industry, Michael practiced as a physician for eleven years. Michael is currently on the boards of GTx Inc, Oxagen / Atopix, Oncoethix, Santarus Inc. and a member of the Strategic Advisory Board of Healthcare Royalty Partners. Previously Dr Carter was on the boards of CancerVax, Genosis, Fulcrum, KuDOS, Micromet and Warner Chilcott.
Follow Michael Carter:
About OncoEthix, SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Hamish Cameron
Venture Partner of SV Health Investors
Hamish Cameron is the Operating Partner at SV Health Investors.
Follow Hamish Cameron:
About Janssen Belgium, SV Health Investors, SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
